Syndax Pharmaceuticals (SNDX) stock is back in focus after the company reported Phase 1/2 SAVE trial data for its all-oral Revuforj-based regimen in heavily pretreated acute myeloid leukemia patients with high-risk mutations.

The SAVE trial update appears to have given the stock a short-term lift, with a 1-day share price return of 1.9% and 7-day share price return of 5.3%. However, the 90-day share price return is down 24.1%, while the 1-year total shareholder return is 78.1%. This suggests that long-term holders have still seen strong gains despite recent weakness.

If this kind of biotech news has your attention, it can be helpful to see what else is moving in related areas by reviewing 40 healthcare AI stocks.

So with Syndax now trading at US$18.25, a value score of 4, an intrinsic value estimate implying a large discount, and shares still well below recent 90 day levels, is this a reset the market is mispricing or already factoring in future growth?

Most Popular Narrative: 53.8% Undervalued

At a last close of $18.25 against a narrative fair value of $39.50, Syndax is framed as heavily discounted, with that gap hinging on a few big clinical and commercial swing factors.

Late-stage pipeline advancements (including frontline trials, lifecycle management, and expansion into new indications like IPF for Niktimvo), coupled with strong clinical data and market-leading positions in precision oncology, provide potential long-term growth avenues. These are aligned with demand for innovative, targeted therapies and support the possibility of multi-year earnings momentum.

Want to see what is built into that growth story? Revenue compounding, margin expansion, and a future earnings profile all factor into this fair value. The key is how quickly those late-stage assets scale, and what profitability looks like if they do.

Result: Fair Value of $39.50 (UNDERVALUED)

However, this hinges heavily on Revuforj and Niktimvo, so any clinical or regulatory setback, or slower than expected adoption, could quickly weaken that undervaluation case.

Next Steps

If this setup feels cautiously optimistic to you, move quickly from headline impressions to the underlying numbers and assess the 2 key rewards.

Looking for more investment ideas?

If Syndax has sparked your interest, do not stop here. Use the Simply Wall Street Screener to uncover other stocks that might suit your goals and risk comfort.

• Target potential mispriced opportunities by scanning 44 high quality undervalued stocks that combine quality fundamentals with attractive valuation signals.
• Prioritize resilience with 71 resilient stocks with low risk scores if you want companies that score well on stability and downside protection.
• Spot early-stage prospects before the crowd by reviewing the 24 elite penny stocks with strong financials that still pass solid financial checks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.